DIACOMIT 500 MG
STIRIPENTOL : 500 MG · DIN 02398966 · BIOCODEX SAS
Health Canada status: MARKETED
What is DIACOMIT?
DIACOMIT 500 MG contains STIRIPENTOL : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02398966, held by BIOCODEX SAS, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 01-May-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIACOMIT used for?
Adjunctive therapy with clobazam and valproate for refractory generalized tonic-clonic seizures in patients with Dravet syndrome (SMEI) not controlled by clobazam and valproate alone.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02398966 |
|---|---|
| Brand name | DIACOMIT |
| Generic / active ingredient | STIRIPENTOL : 500 MG |
| Manufacturer | BIOCODEX SAS |
| Strength | 500 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AX17 STIRIPENTOL |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-May-2013 |
| Original market date | 2013-05-01 00:00:00 |
How is it administered?
Recommended dose: 50 mg/kg/day in 2-3 divided doses. Administer with food. Titrate over 3 days. Adjust clobazam/valproate doses as needed based on side effects.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), though general administration mentions avoiding acidic environments.
How is it supplied?
Capsules: Bottles of 60. Powder for suspension: Cartons of 30, 60, or 90 sachets.
Contraindications
Hypersensitivity to stiripentol or to any ingredient in the formulation or component of the container.
Warnings and precautions
Serious drug interactions; risk of delirium/hallucinations; neutropenia and thrombocytopenia; somnolence; suicidal ideation; growth monitoring required due to GI effects.
What can be used instead?
Other Canadian products sharing ATC code N03AX17 STIRIPENTOL. 3 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DIACOMIT | 250 MG | CAPSULE | BIOCODEX SAS | MARKETED | DIN 02398958 |
| DIACOMIT | 250 MG | POWDER FOR SUSPENSION | BIOCODEX SAS | MARKETED | DIN 02398974 |
| DIACOMIT | 500 MG | POWDER FOR SUSPENSION | BIOCODEX SAS | DORMANT | DIN 02398982 |
Who else supplies STIRIPENTOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. STIRIPENTOL appears in 19 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.